All Stories

  1. Prostanoid receptors in GtoPdb v.2025.3
  2. Endothelium-derived C-type natriuretic peptide offsets the pathogenesis of pulmonary hypertension
  3. MicroRNA regulation of PPARG Signalling: Therapeutic implications for pulmonary hypertension
  4. Circulating large extracellular vesicles as diagnostic biomarkers of indeterminate thyroid nodules: multi-platform omics analysis
  5. Functional Genomics Validation of PPAR gamma Signalling in PASMCs: Therapeutic Implications for Pulmonary Arterial Hypertension
  6. Thomas (Tom) B. Bolton – a major force in smooth muscle research
  7. 75 CIRCULATING EXTRACELLULAR VESICLES AS DIAGNOSTIC BIOMARKERS FOR INDETERMINATE THYROID NODULES
  8. Relative Recovery of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Rats
  9. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  10. Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension
  11. Prostanoid receptors in GtoPdb v.2023.1
  12. OGC P05 Liquid biopsy in oesophageal cancer: a systematic review of blood biomarkers for early diagnosis
  13. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature
  14. SPOD2 Microvesicles as biomarkers for the screening of colorectal neoplasm
  15. The role of microvesicles as biomarkers in the screening of colorectal neoplasm
  16. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  17. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
  18. Prostanoid receptors in GtoPdb v.2021.2
  19. Prostanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  20. International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2Receptors (EP1–4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions
  21. Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients
  22. Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension
  23. Synthetic routes to treprostinil N-acyl methylsulfonamide
  24. Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity
  25. Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  26. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  27. Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension
  28. Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  29. Exploring the enzymatic degradation of poly(glycerol adipate)
  30. Selexipag in the management of pulmonary arterial hypertension: an update
  31. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension
  32. Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
  33. RALINEPAG REDUCES PULMONARY VASCULAR RESISTANCE (PVR) IN A PHASE 2 STUDY CONFIRMING PRECLINICAL FINDINGS ON PROSTACYCLIN (IP) RECEPTORS IN HUMAN TISSUES
  34. Impact of treprostinil on dynamin-related protein 1 (DRP1) and mitochondrial fragmentation in pulmonary arterial hypertension (PAH).
  35. Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells
  36. Improving Interpretation of Cardiac Phenotypes and Enhancing Discovery With Expanded Knowledge in the Gene Ontology
  37. EP4 agonists have reduced bronchodilation activity in patients with Group III pulmonary hypertension
  38. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  39. The non-prostanoid IP receptor agonist, APD811 (ralinepag) has potent antiproliferative and vasorelaxant properties in human pulmonary artery
  40. 5021APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery
  41. Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart
  42. Inotropic Effects of Prostacyclins on the Right Ventricle Are Abolished in Isolated Rat Hearts With Right-Ventricular Hypertrophy and Failure
  43. Abstracts from the 10th World Congress for Microcirculation
  44. Differential action of beraprost isomers on prostacyclin (IP) receptors and PPARβ in pulmonary arteries
  45. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents
  46. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors
  47. Inhibition of Phosphodiesterase 2 Augments cGMP and cAMP Signaling to Ameliorate Pulmonary Hypertension
  48. Counteracting effects of treprostinil and endothelin (ET-1) receptor antagonists (ETRAs) on endothelin-1, ETB receptor and ECE-1 levels in pulmonary smooth muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension (PAH)
  49. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor
  50. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins
  51. Attenuated vascular responsiveness to K+ channel openers in diabetes mellitus: the differential role of reactive oxygen species
  52. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist
  53. Inhibition of vascular adenosine triphosphate-sensitive potassium channels by sympathetic tone during sepsis
  54. BK Large Conductance Ca2+-Activated K+ Channel-Deficient Mice are not Resistant to Hypotension and Display Reduced Survival Benefit Following Polymicrobial Sepsis
  55. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors
  56. Retraction Note: The large-conductance Ca2+-activated K+ channel is essential for innate immunity
  57. Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension
  58. Ca2+/calcineurin regulation of cloned vascular KATP channels: crosstalk with the protein kinase A pathway
  59. VARIABLE EFFECTS OF INHIBITING iNOS AND CLOSING THE VASCULAR ATP-SENSITIVE POTASSIUM CHANNEL (VIA ITS PORE-FORMING AND SULFONYLUREA RECEPTOR SUBUNITS) IN ENDOTOXIC SHOCK
  60. Different calcium mobilisation pathways underlie the changes in vascular reactivity to norepinephrine and vasopressin in septic shock
  61. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis*
  62. IP receptor-dependent activation of PPARγ by stable prostacyclin analogues
  63. Stoking Up BK Ca Channels in Hemorrhagic Shock
  64. Nuclear translocation of calcineurin Aβ but not calcineurin Aα by platelet-derived growth factor in rat aortic smooth muscle
  65. Endothelium-derived hyperpolarization factor (EDHF) is up-regulated in a pig model of acute liver failure
  66. Vasopressin: Mechanisms of action on the vasculature in health and in septic shock
  67. Role of KATP channels in sepsis
  68. Functional Expression of Inward Rectifier Potassium Channels in Cultured Human Pulmonary Smooth Muscle Cells: Evidence for a Major Role of Kir2.4 Subunits
  69. Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprost via a cyclic AMP-independent mechanism
  70. Opportunities to Replace the Use of Animals in Sepsis Research
  71. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide
  72. The pore‐forming subunit of the KATP channel is an important molecular target for LPS‐induced vascular hyporeactivity in vitro
  73. The large-conductance Ca2+-activated K+ channel is essential for innate immunity
  74. The BK Channel
  75. Do Anionic Phospholipids Serve as Cofactors or Second Messengers for the Regulation of Activity of Cloned ATP-Sensitive K + Channels?
  76. Different molecular sites of action for the KATP channel inhibitors, PNU‐99963 and PNU‐37883A
  77. NO contributes to EDHF-like responses in rat small arteries: a role for NO stores
  78. The molecular site of action of KATP channel inhibitors determines their ability to inhibit iNOS-mediated relaxation in rat aorta
  79. Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the α or β catalytic subunit
  80. Assembly Limits the Pharmacological Complexity of ATP-sensitive Potassium Channels
  81. Terlipressin for norepinephrine-resistant septic shock
  82. Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery
  83. The Molecular Composition of KATP Channels in Human Pulmonary Artery Smooth Muscle Cells and Their Modulation by Growth
  84. Temporal variation in endotoxin‐induced vascular hyporeactivity in a rat mesenteric artery organ culture model
  85. A mechanism for ATP-sensitive potassium channel diversity: Functional coassembly of two pore-forming subunits
  86. Calcium Modulation of Vascular Smooth Muscle ATP-Sensitive K + Channels
  87. Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta
  88. Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost
  89. Potassium channels in the vasculature
  90. Abnormal Activation of K+Channels Underlies Relaxation to Bacterial Lipopolysaccharide in Rat Aorta
  91. Ca(2+)-activated Cl- currents in pulmonary arterial myocytes
  92. Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates in isolated rabbit pulmonary myocytes
  93. Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates in isolated rabbit pulmonary myocytes
  94. Ca(2+)-activated Cl- and K+ channels and their modulation by endothelin-1 in rat pulmonary arterial smooth muscle cells
  95. KATP channels: fact or artefact?: commentaries
  96. Properties of the ATP-sensitive K+ current activated by levcromakalim in isolated pulmonary arterial myocytes
  97. Augmentation by intracellular ATP of the delayed rectifier current independently of the glibenclamide-sensitive K-current in rabbit arterial myocytes
  98. Calcium Channels and Vasodilation
  99. ATP-sensitive K+ channels mediate vasodilation produced by lemakalim in rabbit pulmonary artery
  100. Role for diacylglycerol in mediating the actions of ACh on M-current in gastric smooth muscle cells
  101. ATP-sensitive K+ channels regulate resting potential of pulmonary arterial smooth muscle cells
  102. Both membrane stretch and fatty acids directly activate large conductance Ca2+‐activated K+ channels in vascular smooth muscle cells
  103. Outward currents in rabbit pulmonary artery cells dissociated with a new technique
  104. Modulation of calcium movements by nitroprusside in isolated vascular smooth muscle cells
  105. Dual regulation of M current in gastric smooth muscle cells: β-adrenergic-muscarinic antagonism
  106. Substance P, like acetylcholine, augments one type of Ca2+ current in isolated smooth muscle cells
  107. Regulation of one type of Ca 2+ current in smooth muscle cells by diacylglycerol and acetylcholine
  108. Neurotransmitter Regulation of Ionic Channels in Freshly Dissociated Smooth Muscle Cellsa
  109. Acetylcholine increases voltage-activated Ca2+ current in freshly dissociated smooth muscle cells.
  110. Endothelial‐dependent relaxant actions of carbachol and substance P in arterial smooth muscle
  111. The diverse effects of noradrenaline and other stimulants on 86Rb and 42K efflux in rabbit and guinea‐pig arterial muscle.